Skip to main content
. 2024 Mar 25;12(4):731. doi: 10.3390/biomedicines12040731

Figure 1.

Figure 1

Management of particular miRNA molecules (miR-15a-5p, miR-126-3p, miR-142-5p, miR-21-5p and miR-150-5p) in groups with Graves’ disease (GD), with Hashimoto’s thyroiditis (HT) and with nodular goiter and in control group.